98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940092 | PMC |
http://dx.doi.org/10.3345/cep.2020.01228 | DOI Listing |
Minerva Urol Nephrol
September 2025
Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy -
Chronic kidney disease (CKD) affects almost 10% of the global population and is a significant health issue. The presence of CKD increases the risk of fatal and non-fatal cardiovascular events, overall mortality, and progression of renal damage leading to kidney failure. Inhibiting the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme inhibitor or angiotensin II receptor blockers reduces proteinuria and slows eGFR decline in CKD patients.
View Article and Find Full Text PDFClin Transl Med
September 2025
Department of Cardiology, Guangzhou Red Cross Hospital of Ji-Nan University, Guangzhou, China.
Background: To investigate the role of self-peripheral blood mesenchymal stem cell (PBMSC)-derived exosomes (Exos) in enhancing renal sympathetic denervation (RD)-mediated heart regeneration following myocardial infarction (MI) in a porcine model.
Methods: Pigs (ejection fraction [EF] < 40% post-MI) were randomised to early sham RD or RD. At 2 weeks post-MI, autologous PBMSC-Exos were collected.
Pediatr Res
September 2025
Department of Pediatrics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Background: Glucagon-like peptide-1 (GLP-1) shows promise for treating hyperoxia-induced bronchopulmonary dysplasia (BPD), but its mechanisms remain unclear. This study investigated the effects and potential mechanisms of GLP-1 using a hyperoxia-induced neonatal BPD mouse model.
Methods: Sprague-Dawley (SD) newborn rats were randomly assigned to four groups: control, hyperoxia, hyperoxia+Liraglutide, and hyperoxia+Liraglutide+A779.
J Physiol
September 2025
Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Copenhagen, Denmark.
Individual responses to exercise training vary widely, shaping athletic performance, rehabilitation outcomes and long‑term health trajectories. This review synthesizes evidence on how angiotensin-converting enzyme (ACE) activity, influenced by genetic variation, epigenetic regulation and pharmacological modulation, shapes adaptations in skeletal muscle hypertrophy, cardiac remodelling, erythropoiesis, endurance capacity and injury susceptibility. We highlight ACE's nuanced role, showing that pharmacological inhibition selectively attenuates cardiac and haematological adaptations, such as haemoglobin mass and lean body mass, without affecting peripheral muscle adaptations and aerobic performance.
View Article and Find Full Text PDFiScience
September 2025
Laboratory of Experimental Oncology, Division Oncology and Hematology, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Compared to bortezomib treatment, multiple myeloma (MM) treatment with the proteasome inhibitor carfilzomib is associated with a higher incidence of cardiovascular adverse events. However, the mechanism underlying such cardiopathogenic side effects in MM patients remains elusive. Here, we show that carfilzomib-specific proteasome inhibition profoundly impairs cardiomyocyte contractility.
View Article and Find Full Text PDF